Business Context and Reporting Period
Company: American Shared Hospital Services (ASHS)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2026
Business Overview: ASHS provides turn-key technology solutions for stereotactic radiosurgery and advanced radiation therapy. Operations are divided into two segments: Leasing (medical equipment leasing to hospitals) and Direct Patient Services (stand-alone facilities in the U.S., Peru, Ecuador, and Mexico).
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $7,084,000 | $6,112,000 |
| Gross Margin | $1,288,000 (18.2%) | $942,000 (15.4%) |
| Operating Loss | $(924,000) | $(1,299,000) |
| Net Loss | $(962,000) | $(912,000) |
| Net Loss Attributable to ASHS | $(612,000) | $(625,000) |
| Loss Per Share (Diluted) | $(0.09) | $(0.10) |
| Cash and Cash Equivalents | $4,973,000 | $11,241,000 |
| Total Current Liabilities | $23,718,000 | $23,444,000 |
| Long-Term Debt (Current Portion) | $16,843,000 | $17,294,000 |
| Net Cash Provided by Operating Activities | $2,149,000 | $2,503,000 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased by $972,000 (15.9%) year-over-year.
- Leasing Segment: Increased $29,000 to $3,020,000, driven by higher procedure volumes for Gamma Knife and Proton Beam Radiation Therapy (PBRT).
- Direct Patient Services: Increased $943,000 to $4,064,000, primarily due to higher volumes at Rhode Island facilities and the Puebla, Mexico location.
- Cost Structure: Total costs of revenue rose $626,000 to $5,796,000.
- Depreciation: Decreased $156,000 due to asset expirations and full depreciation of certain Rhode Island assets.
- Operating Costs: Increased $582,000, largely attributed to higher operating costs at the newly acquired Rhode Island facilities.
- Profitability: Operating loss improved by $375,000 to $(924,000). Net loss attributable to ASHS narrowed slightly by $13,000.
- Liquidity: Cash and cash equivalents decreased significantly from $11.24 million in Q1 2025 to $4.97 million in Q1 2026, despite positive operating cash flow, due to debt principal payments and distributions to non-controlling interests.
Guidance, Outlook, Risks, and Contingencies
Going Concern and Debt Covenants
Critical Risk: The filing explicitly states that conditions raise substantial doubt about the Company's ability to continue as a going concern.
- Event of Default: ASHS is in default under its Credit Agreement with Fifth Third Bank due to failure to meet the Minimum Cash Covenant ($5.0 million), fixed-charge coverage ratio, and debt-to-EBITDA ratio as of September 30, 2025 and December 31, 2025.
- Maturity Date: The Credit Agreement matured on April 9, 2026. The Company did not satisfy all outstanding obligations on this date.
- Acceleration Risk: Lenders (Fifth Third and DFC) have the right to accelerate payment obligations. If accelerated, the Company does not have sufficient cash to repay.
- Current Status: ASHS is in discussions with Fifth Third regarding an amendment and extension of the maturity date. No assurance of success is provided.
Other Risks and Commitments
- Capital Commitments: The Company has $7.88 million in commitments to purchase/install Gamma Knife and LINAC systems and $5.71 million in service commitments.
- Internal Controls: Disclosure controls and procedures were deemed not effective due to a material weakness regarding insufficient personnel and resources with accounting experience. Remediation is ongoing.
- Related Party Transactions: Significant transactions exist with Elekta (manufacturer of Gamma Knife), including equipment purchases and service costs.
Investor Verification Checklist
- Debt Extension Status: Verify if ASHS has successfully secured an extension or waiver from Fifth Third Bank to avoid immediate acceleration of the $16.8 million debt obligation.
- Cash Runway: Assess if the current cash balance ($4.97 million) is sufficient to cover operating costs and mandatory debt service without further financing.
- Internal Control Remediation: Review progress on hiring accounting personnel and stabilizing the revenue cycle management for Rhode Island facilities.
- Segment Performance: Monitor the profitability of the Direct Patient Services segment, which currently drives revenue growth but also incurs higher operating costs and losses.
- Capital Expenditure Funding: Confirm how the $7.88 million in equipment commitments will be funded given the current liquidity constraints and covenant defaults.